Semaglutide's FDA Approval: A New Era for MASH Treatment
The ESSENCE of hope: what semaglutide's Food and Drug Administration approval means for metabolic dysfunction-associated steatohepatitis.
Background
For decades, Metabolic Dysfunction-Associated Steatohepatitis (MASH), formerly known as Non-Alcoholic Steatohepatitis (NASH), has been a growing global health concern, characterized by liver inflammation, fat accumulation, and progressive fibrosis (scarring) that can lead to cirrhosis, liver failure, and liver cancer. Despite its prevalence, affecting millions worldwide, there has been a critical lack of FDA-approved pharmacological treatments specifically designed to address the underlying pathology of MASH.